Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

被引:158
作者
Lee, B. [1 ,2 ,3 ]
Lipton, L. [2 ,4 ,5 ]
Cohen, J. [6 ,7 ]
Tie, J. [1 ,2 ,3 ,4 ]
Javed, A. A. [6 ,7 ]
Li, L. [8 ]
Goldstein, D. [9 ]
Burge, M. [10 ]
Cooray, P. [11 ]
Nagrial, A. [12 ]
Tebbutt, N. C. [13 ]
Thomson, B. [3 ,14 ]
Nikfarjam, M. [3 ,13 ]
Harris, M. [15 ]
Haydon, A. [16 ]
Lawrence, B. [17 ]
Tai, D. W. M. [18 ]
Simons, K. [3 ,19 ]
Lennon, A. M. [6 ,7 ]
Wolfgang, C. L. [6 ,7 ]
Tomasetti, C. [6 ,7 ,8 ]
Papadopoulos, N. [6 ,7 ]
Kinzler, K. W. [6 ,7 ]
Vogelstein, B. [6 ,7 ]
Gibbs, P. [1 ,2 ,3 ,4 ]
机构
[1] Walter & Eliza Hall Inst Med Res, Div Syst Biol & Personalised Med, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[3] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia
[4] Western Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[5] Cabrini Hlth, Dept Med Oncol, Malvern, Australia
[6] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr, Baltimore, MD USA
[7] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD USA
[8] Johns Hopkins Univ, Sch Med, Dept Oncol, Div Biostat & Bioinformat, Baltimore, MD 21205 USA
[9] Prince Wales Hosp, Dept Med Oncol, Randwick, NSW, Australia
[10] Royal Brisbane Hosp, Dept Med Oncol, Brisbane, Qld, Australia
[11] Eastern Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[12] Crown Princess Mary Canc Ctr Westmead, Dept Med Oncol, Westmead, NSW, Australia
[13] Olivia Newton John Canc & Wellness Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[14] Royal Melbourne Hosp, Dept Surg, Melbourne, Vic, Australia
[15] Monash Med Ctr, Dept Med Oncol, Clayton, Vic, Australia
[16] Alfred Hosp, Dept Med Oncol, Melbourne, Vic, Australia
[17] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand
[18] Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
[19] Univ Melbourne, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia
基金
美国国家卫生研究院;
关键词
circulating tumor DNA; pancreatic ductal adenocarcinoma; pancreatic cancer; liquid biopsy; biomarkers; adjuvant therapy; PLASMA DNA; MUTATIONS; QUANTIFICATION; GEMCITABINE;
D O I
10.1093/annonc/mdz200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In early-stage pancreatic cancer, there are currently no biomarkers to guide selection of therapeutic options. This prospective biomarker trial evaluated the feasibility and potential clinical utility of circulating tumor DNA (ctDNA) analysis to inform adjuvant therapy decision making. Materials and methods: Patients considered by the multidisciplinary team to have resectable pancreatic adenocarcinoma were enrolled. Pre- and post-operative samples for ctDNA analysis were collected. PCR-based-SafeSeqS assays were used to identify mutations at codon 12, 13 and 61 of KRAS in the primary pancreatic tumor and to detect ctDNA. Results of ctDNA analysis were correlated with CA19-9, recurrence-free and overall survival (OS). Patient management was per standard of care, blinded to ctDNA data. Results: Of 112 patients consented pre-operatively, 81 (72%) underwent resection. KRAS mutations were identified in 91% (38/42) of available tumor samples. Of available plasma samples (N = 42), KRAS mutated ctDNA was detected in 62% (23/37) preoperative and 37% (13/35) post-operative cases. At a median follow-up of 38.4 months, ctDNA detection in the pre-operative setting was associated with inferior recurrence-free survival (RFS) [hazard ratio (HR) 4.1; P = 0.002)] and OS (HR 4.1; P = 0.015). Detectable ctDNA following curative intent resection was associated with inferior RFS (HR 5.4; P < 0.0001) and OS (HR 4.0; P = 0.003). Recurrence occurred in 13/13 (100%) patients with detectable ctDNA post-operatively, including in seven that received gemcitabine-based adjuvant chemotherapy. Conclusion: ctDNA studies in localized pancreatic cancer are challenging, with a substantial number of patients not able to undergo resection, not having sufficient tumor tissue for analysis or not completing per protocol sample collection. ctDNA analysis, pre-and/or post-surgery, is a promising prognostic marker. Studies of ctDNA guided therapy are justified, including of treatment intensification strategies for patients with detectable ctDNA post-operatively who appear at very high risk of recurrence despite gemcitabine-based adjuvant therapy.
引用
收藏
页码:1472 / 1478
页数:7
相关论文
共 20 条
  • [1] AIHW (Australian Institute of Health and Welfare), AUSTR CANC INC MORT
  • [2] MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES
    ALMOGUERA, C
    SHIBATA, D
    FORRESTER, K
    MARTIN, J
    ARNHEIM, N
    PERUCHO, M
    [J]. CELL, 1988, 53 (04) : 549 - 554
  • [3] [Anonymous], 2019, UPDATE ON ABRAXANE C
  • [4] Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer
    Bernard, Vincent
    Kim, Dong U.
    San Lucas, F. Anthony
    Castillo, Jonathan
    Allenson, Kelvin
    Mulu, Feven C.
    Stephens, Bret M.
    Huang, Jonathan
    Semaan, Alexander
    Guerrero, Paola A.
    Kamyabi, Nabiollah
    Zhao, Jun
    Hurd, Mark W.
    Koay, Eugene J.
    Taniguchi, Cullen M.
    Herman, Joseph M.
    Javle, Milind
    Wolff, Robert
    Katz, Matthew
    Varadhachary, Gauri
    Maitra, Anirban
    Alvarez, Hector A.
    [J]. GASTROENTEROLOGY, 2019, 156 (01) : 108 - +
  • [5] Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
    Bettegowda, Chetan
    Sausen, Mark
    Leary, Rebecca J.
    Kinde, Isaac
    Wang, Yuxuan
    Agrawal, Nishant
    Bartlett, Bjarne R.
    Wang, Hao
    Luber, Brandon
    Alani, Rhoda M.
    Antonarakis, Emmanuel S.
    Azad, Nilofer S.
    Bardelli, Alberto
    Brem, Henry
    Cameron, John L.
    Lee, Clarence C.
    Fecher, Leslie A.
    Gallia, Gary L.
    Gibbs, Peter
    Le, Dung
    Giuntoli, Robert L.
    Goggins, Michael
    Hogarty, Michael D.
    Holdhoff, Matthias
    Hong, Seung-Mo
    Jiao, Yuchen
    Juhl, Hartmut H.
    Kim, Jenny J.
    Siravegna, Giulia
    Laheru, Daniel A.
    Lauricella, Calogero
    Lim, Michael
    Lipson, Evan J.
    Marie, Suely Kazue Nagahashi
    Netto, George J.
    Oliner, Kelly S.
    Olivi, Alessandro
    Olsson, Louise
    Riggins, Gregory J.
    Sartore-Bianchi, Andrea
    Schmidt, Kerstin
    Shih, Ie-Ming
    Oba-Shinjo, Sueli Mieko
    Siena, Salvatore
    Theodorescu, Dan
    Tie, Jeanne
    Harkins, Timothy T.
    Veronese, Silvio
    Wang, Tian-Li
    Weingart, Jon D.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)
  • [6] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) : 2395 - 2406
  • [7] Detection and quantification of mutations in the plasma of patients with colorectal tumors
    Diehl, F
    Li, M
    Dressman, D
    He, YP
    Shen, D
    Szabo, S
    Diaz, LA
    Goodman, SN
    David, KA
    Juhl, H
    Kinzler, KW
    Vogelstein, B
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) : 16368 - 16373
  • [8] Circulating mutant DNA to assess tumor dynamics
    Diehl, Frank
    Schmidt, Kerstin
    Choti, Michael A.
    Romans, Katharine
    Goodman, Steven
    Li, Meng
    Thornton, Katherine
    Agrawal, Nishant
    Sokoll, Lori
    Szabo, Steve A.
    Kinzler, Kenneth W.
    Vogelstein, Bert
    Diaz, Luis A., Jr.
    [J]. NATURE MEDICINE, 2008, 14 (09) : 985 - 990
  • [9] Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer
    Hadano, Naoto
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Hashimoto, Yasusi
    Kondo, Naru
    Nakagawa, Naoya
    Sueda, Taijiro
    Hiyama, Eiso
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (01) : 59 - 65
  • [10] Detection and quantification of rare mutations with massively parallel sequencing
    Kinde, Isaac
    Wu, Jian
    Papadopoulos, Nick
    Kinzler, Kenneth W.
    Vogelstein, Bert
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (23) : 9530 - 9535